Compare 3M Company (MMM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs TG Therapeutics Inc — how do they compare? 3M Company trades at $160.09 (market cap $84.36B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: 3M Company is far larger — about 10.3× TG Therapeutics Inc's market cap, and 3M Company pays a 1.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and TG Therapeutics Inc for 16 Days on average.
| MMM | TGTX | |
|---|---|---|
Market Cap | $84.36B | $8.16B |
Volume | 2,325,301 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $183.79 | $59.06 |
52-Week Low | $141.10 | $26.94 |
Typical Hold Time | 169 Days | 16 Days |
Enterprise Value | $93.58B | $8.37B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $159.96, down 1.33% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.40 versus $2.25 expected, and maintains a robust net income margin of 11.9%. Recent news highlights operational momentum, including raised guidance and progress on litigation management. Cash flow from operations improved to $2.31 billion in 2025, though net cash flow was negative $319 million due to financing activities.
The outlook is mixed; analyst consensus is a Buy with a $191 price target, implying 19% upside, but technical indicators suggest near-term pressure. Key risks include high debt levels, weak consumer segment demand, and cost pressures. Earnings growth and margin expansion remain critical for sustained stock appreciation amid competitive and macroeconomic challenges.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
